Skip to content

Clinical trials

Completed Acquired Immunodeficiency Syndrome trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Acquired Immunodeficiency Syndrome Status: Completed Country / region: United States Clear all

1,366 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20007
20019
200216
200314
200418
200531
200625
200725
200839
200934
201040
201145
201235
201337
201446
201535
201642
201745
201861
201964
202040
202135
202235
202320
20247

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed1,366

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)278
ViiV Healthcare85
University of California, San Francisco40
Pfizer30
Gilead Sciences29
Glaxo Wellcome26
Bristol-Myers Squibb25
Hoffmann-La Roche25
Emory University23
Johns Hopkins University23

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Acquired Immunodeficiency Syndrome1,366
HIV Infections777
AIDS-Related Complex227
AIDS-Related Opportunistic Infections112
Infections92
Substance-Related Disorders51
Pneumonia, Pneumocystis49
Cytomegalovirus Infections44
Sarcoma, Kaposi42
Cytomegalovirus Retinitis40

Trials

Showing 1 to 25 of 1,366. Each trial links to its page on Pharma Observatory.

1,266 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.